2025-11-14
Randomized Controlled Clinical Trial of Shenzhuo Formula in the Treatment of Macroalbuminuria in Diabetic Kidney Disease and Its Inflammation-Modulating Mechanisms
2025-11-14 • Wang Anzhu, Huang Yi-shan, Wei Yu, Zhang Lili, Chen Hong-dong, Wang Xiao-qing, Cui Zhimei, Wang Bin, Liu Wei, Chen Chao, Lei Ye, Zheng Zhong-hua, W...
Abstract Background Shenzhuo Formula (SZF), a modified Didang Tang, is used for diabetic kidney disease (DKD), though high-quality evidence is limited. Methods In a randomized, double-blind, double-dummy, active-controlled, multicenter trial, irbesartan was the control. A Bayesian model assessed efficacy. Mechanistic studies included Olink inflammation proteomics, single-cell RNA sequencing (scRNA-seq) of KK-Ay mouse kidneys, and in vivo experiments. Results 120 DKD patients with macroalbuminuria were randomized (…